healiva® is a patient centric Swiss Biotech company, delivering precision medicine to improve patients’ quality of life. We use a multi-pronged approach to address patient needs by combining enzyme technology, medical devices, and cell therapy to deliver tailored solutions for chronic wounds. We are the first Biotech to offer multiple end-to-end, intuitive wound care products that can be personalised whilst remaining affordable.
Our mission is to heal life, by leveraging best-in-class innovations including enzyme technologies, stem cells, natural, and synthetic molecules to deliver personalised, and precision medicine. There remains a major gap in the current treatment paradigm. No permanent therapy for non-healing wounds currently exists.Who we are Our Approach News
1. C. Lindholm & R. Searle; Int Wound J 2016
2. K. Alexiadou & J. Doupis; Diabetes Ther. 2012
3. Marketsandmarkets.com report April 2021
Owing to our Swiss-Italian heritage, we take the concept of regenerative medicine as coined by William Haseltine at a conference on Lake Como in 1999, a few minutes drive from our office. We aim to provide solutions and treatments for chronic diseases by combining emerging tools and cutting edge technologies from the fields of tissue engineering, cell transplantation, stem cell biology, biomechanics, biochemistry and immunology.
Our pipeline includes a scalable, automated cell therapy solution with a focus on chronic wounds arising from metabolic diseases. We aim to provide patients and healthcare practitioners with efficient tools and precision solutions for tissue replacement, repair, or regeneration.
With our naturally occurring medical grade enzymes, produced with proprietary technologies by our partner Bioseutica BV, we provide patients and healthcare practitioners with efficient alternative solutions to chemical or surgical interventions.
Leveraging emerging medical device technologies, we will deliver next generation personalised therapies for chronic wounds. Our autologous medical device enables cost-effective, rapid grafting of wounds at the point of care.
Dr. Priyanka Dutta-Passecker excels in combining her scientific prowess (PhD in Neuroscience from Trinity College Dublin, Ireland) with her qualified business expertise (a dual MBA from WU Executive Academia, Austria and Carlson Business School, Minnesota, USA ) to translate scientific advances to patient oriented solutions. She has gained 12+ years of experience in pharma and biotech with key accomplishments in enzyme technology and cell therapy from Novartis (CH), UCB( B), Axol Bioscience ( UK) and Bioseutica (CH). Outside of her professional life she is an energetic supporter of diversity and female empowerment that culminated in her co-foundation of the WU EA Female Leaders Network in Vienna, Austria that has grown into the biggest female leadership network in central Europe. Priyanka shares her gained experience and helps train the next generation of Entrepreneurs at the School of Medicine, Trinity College Dublin Ireland.
Valerio Maria Ferrari was born in Milan and has two passions: architecture, with a degree at Milan Politecnico, and biotechnology, particularly in the development of natural enzymes. He founded Bioseutica BV with his brother in 2006 and assumed the role of Chairman in 2011. Bioseutica acquired Neova Technology Inc, Canada and KD Pharma, Germany (currently one of the biggest omega 3 company) in 2008. Bioseutica sold majority of KD Pharma shares to a private equity in 2013 and still stayed as the second largest shareholder of the company. Bioseutica’s history dates back to the discovery of lysozyme by Sir Alexander Fleming in 1922, following which he collaborated with Valerio’s grandfather to pursue the industrial development of this powerful enzyme and continued developing of other natural enzymes.
Paolo Magrì is CEO of the Bioseutica Group, active in the production of pharma grade natural proteins and enzymes. The Group is headquartered in The Netherlands, with offices in Switzerland and production sites in British Columbia (CA).
Mr. Magrì has over 30 years of experience in the active pharmaceutical ingredient (API) industry, and he is currently on the Board of DCAT, where he served as President of the Association for two terms, from 2018 until 2021.
Prior to joining Bioseutica, he was senior VP at Advitech Advisory and Technologies. Previous to that role, he worked at INFA Group as Vice President of corporate business development, and as marketing and sales Director at Sicor and in Teva’s API division, after the acquisition of Sicor by Teva in 2004.
His strong track record in the industry also includes previous roles at Archimica/Pro.Bio.Sint. and Fordras. Mr. Magrì earned his Master’s degree in chemistry and pharmaceutical technology from the University of Milan, Italy.
Business strategy and Entrepreneurship Expert with vast hands on experience in the establishment, management and investment in start-ups. Co- Founder and CEO of a Food tech start up that was later publicly traded (NASDAQ) and acquired by a global corporation. Lead Corp Dev activity: investments and strategic collaborations with food tech startups at a publicly traded leading global F&F corporation. As a CEO of start- up companies has extensive experience in R&D and innovation management and start- up maturation. Brings both corporate, academic & entrepreneurship expertise. As an expert in the Horizon 2020 and EIC accelerator programs, conducted due diligence to hundreds of European based startups. Founder of "Hameizot" a female founder acceleration program. Holds PhD in Strategy and Entrepreneurship, MBA, MSc and BSc in Biology.
Jay is Scientific Advisory Board Member of Healiva SA and has served as Chief Scientific Officer of Bioseutica BV previously. Jay has more than 10 yrs of industrial experience across both pharma and food sectors, in areas of drug development, innovation management, R&D strategy, business development and alliance management. Jay has been associated with Nestle and Novartis during his career and is passionate about microbiome, data analytics, open source software and teaching. Jay received his PhD from the university of Pune, India and MBA from EPFL, Switzerland.
Giuseppe Perale was born in Venice (Italy) in 1978, in 2002 he obtained his Master degree at the Politecnico di Milano in Biomedical Engineering, with curriculum courses from the Medicine Faculty of University of Milan; in 2006 he got his Ph.D. degree in Industrial Bioengineering, at the Politecnico di Milano. Visiting Post Doc at the Imperial College London in 2007, visiting Researcher at the Karolinska Institutet in Stockholm in 2011 and at the IRF “Mario Negri” in 2012, he was Acting Professor of “Formulations Science” at the Politecnico di Milano until Spring 2013. Full Professor of Industrial Bioengineering at the SUPSI Swiss University until 2020. Since 2019 he is Professor of Regenerative Medicine at the Faculty of Biomedical Sciences of the University of Southern Switzerland, USI, in Lugano. Since 2019, he is also permanent visiting Professor at Ludwig Boltzmann Institute for Experimental and Clinical Traumatology in Vienna. Following the so-called “nature inspired” philosophy, his scientific and research interests are focused on regenerative medicine, tissue engineering and physical chemistry applied to biomaterials for medical applications. He’s author in over 150 international publications, 4 academic books and 6 international patent families.
He is also the Austrian Honorary Consul for Tessin.
Dr. Andreas Emmendoerffer MD is our Operational and Regulatory lead, bringing wound management insight, and 20+ years of experience in quality assurance and regulatory affairs. AE has worked for TÜV SÜD, NAMSA, Xeltis, V-Care Biomedical, Euroderm GmbH, Modex Therapeutics SA, and Zyo Biotech GmbH. His experience provides the capability to position and develop products to the exacting requirements of international regulatory bodies.
Eric holds a Ph.D. in biochemistry from Claude Bernard University (Lyon, France) and an Industrial Biology Engineer degree from ‘Conservatoire National des Arts et Métiers’ (Lyon, France).
Eric has over 30 years of experience managing research in the biotechnology and pharmaceutical industries. Eric was most recently director of the Nestlé Institute of Health Sciences (Lausanne, Switzerland). Prior to joining Nestlé, Eric was the General Manager of the Swiss operations and the global VP of R&D at HealthPoint Biotherapeutics (Lausanne, Switzerland, Fort Worth, USA). He previously served as VP of R&D at IsoTis Orthobiologics (Lausanne, CH, Bilthoven, NL, Irvine, USA) and as Head of R&D at Modex Therapeutics (Lausanne, Switzerland). Prior to Modex, Eric held R&D management and scientific positions at Gambro (Meyzieu, France) and Mérieux (Lyon, France).
Dr. Davor Ivankovic holds a PhD in Cellular and Molecular Neuroscience from University College London. He brings more than 10 years of experience in biological research, in which time he worked on the mechanisms of fundamental cellular functions in the brain. Davor has experience of medical and grant writing, start-up acceleration, and partnership building.
Healiva is a patient-centric biotech company that delivers precision medicine to improve people’s quality of life. We use a multi-pronged approach to address patient needs by combining enzyme technology, medical devices, and cell therapy to deliver precision solutions for chronic wounds. We are currently looking for an experienced Quality Manager to join us in Lugano.
Healiva is a patient-centric biotech company that delivers precision medicine to improve people’s quality of life. We use a multi-pronged approach to address patient needs by combining enzyme technology, medical devices, and cell therapy to deliver precision solutions for chronic wounds. We are currently looking for an experienced R&D Manager to join us. (Hybrid position).
June 1 2022
LUGANO, Switzerland--(BUSINESS WIRE)--Healiva®, a patient-centric company delivering life-enhancing precision medicine for patients with chronic and acute wounds, announced today the acquisition of two innovative cell therapy assets from Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business. The acquisition enables Healiva® to establish one of the world’s broadest portfolios of affordable, personalized, end-to-end wound care consisting of enzyme technology, autologous & allogenic cell therapies, and medical devices. Financial details have not been disclosed.
November 18 2021
The Association at present counts 27 member companies, with a combined workforce of 2500 employees and a total annual turnover of approximately 2.3 Billion Swiss Francs, (>80% export) accounting for approximately 8% of the cantonal GNP. The actual number of personnel of the companies associated with Farma Industria Ticino averages at 100 employees and is therefore higher than the average associated with the entire industrial sector of Ticino. Representing the vast majority of the companies active in this Italian speaking part of Switzerland, FIT has a great network of know-how and access to skilled and qualified, multilingual human resources, due to its strategical and privileged geographical position that makes Ticino a natural connection between northern and southern Europe.
October 07-10 2021 | Virtual
January 10–12, 2022 | San Francisco
June 13-16, 2022 | San Diego
healiva® is a Bioseutica backed innovative Swiss startup venture located in Lugano combining digital health, enzyme technology and cell therapy to deliver personalised and precision solutions for regenerative biology.